Background-Surgical risk scores do not include frailty assessments (eg, gait speed), which are of particular importance for patients with severe aortic stenosis considering transcatheter aortic valve replacement. Methods and Results-We assessed the association of 5-m gait speed with outcomes in a cohort of 8039 patients who underwent transcatheter aortic valve replacement (November 2011-June 2014) and were included in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. We evaluated the association between continuous and categorical gait speed and 30-day all-cause mortality before and after adjustment for Society of Thoracic Surgeons-predicted risk of mortality score and key variables. Secondary outcomes included in-hospital mortality, bleeding, acute kidney injury, and stroke. The overall median gait speed was 0.63 m/s (25th-75th percentile, 0.47-0.79 m/s), with the slowest walkers (<0.5 m/s) constituting 28%, slow walkers (0.5-0.83 m/s) making up 48%, and normal walkers (>0.83 m/s) constituting 24% of the population. Thirty-day all-cause mortality rates were 8.4%, 6.6%, and 5.4% for the slowest, slow, and normal walkers, respectively (P<0.001). Each 0.2-m/s decrease in gait speed corresponded to an 11% increase in 30-day mortality (adjusted odds ratio, 1.11; 95% confidence interval, 1.01-1.22). The slowest walkers had 35% higher 30-day mortality than normal walkers (adjusted odds ratio, 1.35; 95% confidence interval, 1.01-1.80), significantly longer hospital stays, and a lower probability of being discharged to home.
T ranscatheter aortic valve replacement (TAVR) is an effective, less invasive alternative to surgical aortic valve replacement in select patients with severe aortic stenosis. [1] [2] [3] [4] Because baseline functional status is a known predictor of operative risk, 5 frailty assessment should be particularly relevant for patients with severe aortic stenosis referred for TAVR. Frailty is a clinical state of decreased reserves and vulnerability, thereby increasing susceptibility to adverse outcomes in response to stressors. 6 A recent expert consensus report on TAVR also stated that conventional surgical risk scores are limited by a lack of consideration for functional status and frailty. 7 A simple gait speed test can be used to identify physical frailty with good interrater and retest reliability. 8, 9 Gait speed, alone or incorporated into geriatric rating scales, is associated with mortality among community-dwelling individuals, 10 patients with coronary heart disease, 11 elderly patients with heart failure, 12 and those undergoing cardiac surgery, including aortic valve replacement. 13 Nevertheless, the association between slow gait speed (which is an indicator of physical frailty) and outcomes after TAVR in US clinical practice has not been established. In hopes of better understanding this knowledge gap, we used data from the national Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (STS/ ACC TVT Registry) to describe the association between preprocedural gait speed and outcomes in patients undergoing TAVR. The associations between gait speed and 30-day morbidity and mortality are reported before and after adjustment for the STS-predicted risk of mortality (STS-PROM) surgical risk score.
Methods

The STS/ACC TVT Registry
In response to the Centers for Medicare & Medicaid Services National Coverage Determinations requirement, participation in the STS/ACC TVT Registry is mandatory for all US TAVR centers. 14 Participating centers collect demographics, comorbidities, gait speed (5-m walk), procedural and postoperative details, and outcomes. Data quality checks are implemented at both the National Cardiovascular Data Registry data warehouse and the Duke Clinical Research Institute analytic center, including data feedback reports and consistency checks. Data were collected with the use of standardized definitions and harmonized with the STS national database whenever possible. 3
Gait Speed
Gait speed is a part of the standard preprocedural data entered into the STS/ACC TVT Registry data collection form. Staff at contributing centers received training in performing the 5-m walk test, from which gait speed is assessed. Information on gait speed was collected prospectively on the data collection form as "gait speed performed (yes, no, unable to walk)" and, if the answer was yes, the time it took the patient to walk 5 m. Tests were to be performed in a well-lit hallway with markings at 0 and 5 m. Patients were instructed to walk at a comfortable speed over the 5-m distance. A stopwatch was used to time the first footfall over the 0-m line to the first footfall over the 5-m line, with instructions to repeat the walk 3 times with a brief rest period between trials. The mean of walk times in seconds, measured to the tenth of a second, was used for this analysis. Among patients with recorded gait speed, 89.6% had 3 walk times reported.
Outcomes
The primary outcome was all-cause mortality at 30 days. Secondary outcomes included in-hospital mortality, cardiovascular mortality, postprocedural stroke, acute kidney injury, and bleeding complications. All outcomes were reported by the site to the registry using standardized definitions, including harmonization with Valve Academic Research Consortium definitions for stroke, acute kidney injury, and bleeding. 15, 16 Site-reported strokes were centrally adjudicated. Acute kidney injury was defined as an increase in serum creatinine of ≥150% or ≥0.3 mg/dL from baseline, a newly developed postprocedural value of >4.0 mg/dL, or a need for renal replacement therapy (without previous renal replacement therapy). 15 A life-threatening or disabling bleeding event was defined as fatal bleeding in a critical organ, bleeding causing hypovolemic shock or severe hypotension, or overt bleeding with a drop in hemoglobin of ≥5 g/dL. 15
Statistical Analysis
The distribution of gait speed is shown in the population in which the walk test was performed.
For descriptive purposes, the population was divided into gait speed groups. A cut point of 0.83 m/s has been advocated to define slow walkers undergoing cardiac surgery, 13 whereas a lower cutoff of ≈0.5 m/s has been proposed for patients undergoing TAVR, who are typically older and more functionally compromised. 17 Cut points for this population were chosen on the basis of previous studies and observed gait distribution in the STS/ACC TVT Registry population to create 3 comparison groups: slowest walkers, >10 seconds for 5 m (<0.5 m/s); slow walkers, 6 to ≤10 seconds for 5 m (≥0.5-0.83 m/s); and normal walkers, ≤6 s for 5 m (≥0.83 m/s). Baseline clinical variables, STS-PROM score for isolated valve surgery, 18 and outcomes were compared across the 3 gait speed groups. Continuous variables are presented as medians (25th-75th percentiles), and categorical variables are presented as percentages. Statistical significance was tested with the Cochran-Mantel-Haenszel test.
The association between gait speed and 30-day mortality was analyzed as a continuous variable and across the 3 gait speed groups. Before modeling, the distribution of continuous measures was assessed for potential outliers, which was performed by examining the 1%, 5%, 95%, and 99% quintiles of the univariate distributions. In collaboration with the investigator, if a measurement was judged to be an outlier, then the measurement was set to be the most extreme expected value. The amount of missing data for a prespecified term was also assessed. We determined that there were sufficient data, and imputation was not preformed. The assumption of linearity was tested, and for terms that were in violation, linear splines and the log transformation were used. Logistic regression models were constructed to assess the association of gait speed and 30-day mortality. The model adjustment included STS-PROM score, age, sex, access site, chronic lung disease, baseline renal impairment (current dialysis or creatinine >2.5 mg/dL), and left ventricular ejection fraction <30%. We used the STS-PROM score for isolated valve surgery, 18 which includes 24 variables. Unadjusted and adjusted results are reported as odds ratios (ORs) with 95% confidence interval (CIs). All modeling assumptions were confirmed. To assess the incremental value of gait speed in improving risk classification, the integrated discrimination improvement analysis was performed. Analyses were performed with SAS version 9.2 or higher (SAS Institute, Inc, Cary, NC).
Ethical Considerations
The STS and ACC have signed a Federalwide Assurance for the Protection of Human Subjects with the Department of Health and Human Services, which requires all human subject research to be conducted in compliance with the common rule (45 CFR §46). Registry activities have been approved by a central institutional review board that governs all human subject research conducted by the registry. The Duke University School of Medicine institutional review board granted a waiver of informed consent and authorization for this study.
Results
From November 1, 2011, to June 1, 2014, 18 619 TAVR patients from 315 sites were entered into the STS/ACC TVT Registry. To ensure that sites had adequate experience in performing the gait speed test, we included only those sites with >5 patients reported to the registry (27 sites, 92 patients excluded) and >10% of TAVR procedures with gait speed reported (30 sites, 2046 patients excluded). We excluded urgent or emergent TAVR procedures and procedures performed on patients <65 years of age because gait speed may not reflect preprocedural frailty in these cases (n=2351 patients). Of the remaining 14 130 patients at 256 sites, 58% (n=8206) had recorded gait speed times, 8% (n=1092) were unable to walk, 34% (n=4719) reported no test performed, and 1% (n=113) were missing information. Finally, of the 8206 patients with recorded gait speed times, an additional 167 patients were excluded because of presumed data errors (walk time <2 or >30 seconds). After these exclusions, our final study population comprised 8039 patients from 256 sites ( Figure 1 ).
Characteristics of patients at sites included in the analysis (n=14 130) were compared by whether the gait speed test was performed or not performed or if the patient was unable Table I in the online-only Data Supplement). Minor differences were noted between those in whom a gait speed test was or was not performed, which suggests that there were logistical reasons for not performing the test. Nonetheless, patients who were unable to walk were more often younger and female and more often had diabetes mellitus, previous stroke, chronic lung disease (including use of home oxygen), and a higher New York Heart Association class determined within 2 weeks of the procedure. Patients who were unable to walk also had the highest 30-day mortality rate (9.4%), the longest median length of stay, and the lowest rate of discharge to home (43.8%). They also more often had a New York Heart Association class IV heart failure, had severe chronic lung disease, had home oxygen treatment, and were on dialysis. Although those unable to walk were excluded from gait speed analyses, this group is informative from a prognostic perspective.
Among those who were able to have their gait speed tested (n=8039), the median age was 84 years, and 51% were female. Cardiovascular disease burden was high, with 24% having previous myocardial infarction, 12% having previous stroke, and 33% having previous coronary artery bypass graft surgery ( Table 1) . The median walking time over 5 m was 8 seconds (25th-75th percentile, 4-12 seconds), corresponding to a gait speed of 0.63 m/s (25th-75th percentile, 0.47-0.79 m/s; Figure 2 ). When participants were divided into 3 groups, the slowest walkers (<0.5 m/s) constituted 28%, slow walkers (0.5-0.83 m/s) constituted 48%, and normal walkers (>0.83 m/s) constituted 24% of the population. The slowest walkers were older and more often female and had a higher body mass index and a history of stroke; however, this group less often had experienced a previous myocardial infarction or revascularization procedure. The slowest walkers were also more likely to have chronic lung disease (28.1% versus 25.8% and 22.4% for the slowest, slow, and normal walkers, respectively; P<0.001) and to be on home oxygen (14.3% versus 12.2% and 8.4% for slowest, slow, and normal walkers, respectively; P<0.001). Notably, there was an increase in New York Heart Association class III/IV within 2 weeks of the procedure for those with a lower gait speed, but there was no difference in left ventricular ejection fraction across gait speed groups. Although the slowest gait speed was associated with lower hemoglobin values, there was no difference in creatinine or history of dialysis. Finally, the STS-PROM score indicated greater predicted mortality for those patients with the slowest gait speed.
Thirty-day all-cause mortality was 8.4% for the slowest walkers compared with 6.6% for slow walkers and 5.4% for normal walkers (P<0.001; Table 2 ). In-hospital mortality was also higher among the slowest walkers versus slow and normal walkers (5.6% versus 4.6% and 3.9%, respectively; P=0.032). There were no significant differences in cardiovascular mortality across groups. There were insignificant differences in complications such as stroke and bleeding, but the slowest walkers had a longer hospital length of stay. Furthermore, only 53% of the slowest walkers were discharged to home after the procedure compared with 78% of normal walkers (P<0.0001). An extensive list of in-hospital complications is presented in Table II in the online-only Data Supplement. There were no significant differences between gait speed groups for most complications, with the exception of a higher rate of access-site complications, unplanned vascular surgery, and perforation in the slowest group (Table II in Gait speed (continuous) was significantly associated with 30-day all-cause mortality. For every 0.2-m/s decrease in gait speed, there was a corresponding 16% increase in 30-day mortality (OR, 1.16; 95% CI, 1.06-1.28), which remained significant at 11% after adjustment with STS-PROM score and key covariates (OR, 1.11; 95% CI, 1.01-1.22). Adding gait speed to the model resulted in a modest integrated discrimination improvement of 0.00135 (P=0.0085). Gait speed groups (slowest, slow, and normal) were also associated with 30-day mortality. When predicted mortality by STS-PROM was plotted against observed 30-day mortality, the incremental risk for the same STS-PROM score by the 3 gait speed groups is visible ( Figure 3) . The difference in mortality with gait speed was most pronounced at the higher range of STS-PROM. Finally, in the adjusted model, categorical gait speed showed significantly higher mortality at 30 days for the slowest Figure 4 ). The difference between slow and normal walkers was not significant (OR, 1.08; 95% CI, 0.81-1.42).
Discussion
Gait speed is an indicator of frailty and is independently associated with adverse outcomes in this large national cohort of patients with severe aortic valve disease undergoing TAVR. Furthermore, three quarters of the population is considered frail according to gait speed cut points that identify frailty in community-dwelling older adults 10 or in those who are referred for cardiac surgery. 13 Patients with the slowest gait speeds are more often female and have more heart failure, chronic lung disease, and comorbidity. Gait speed independently predicts 30-day mortality after adjustment for STS-PROM score and key covariates, with every 0.2-m/s decrease in gait speed corresponding to an 11% increase in 30-day mortality. The slowest gait speed group had a 35% higher mortality rate than the normal gait speed group after adjustment. That group also had a longer median length of stay and was less likely to be discharged to home. These findings support using the gait speed test for patients referred for TAVR, given that gait speed adds easy-to-obtain functional information beyond that reflected in established risk scores. We found that normal gait speed in patients considering TAVR was indicative of those who are more fit, whereas the slowest gait speed identifies patients in need of further assessment.
Our study adds to earlier work that has established that patients undergoing TAVR are frail and at increased risk. Despite the fact that existing small studies on TAVR patients have found that the majority of this population is frail, no study has focused on gait speed alone as an indicator of frailty. Ewe et al 19 concluded that frailty, assessed by the Fried Frailty Criteria, 6 was an independent predictor of the combined end point of death and cardiovascular morbidity at 6 months in 147 patients (hazard ratio, 4.20; 95% CI, 2.00-8.84). Stortecky et al 20 found that multiple frailty assessments were associated with mortality, including the Mini Nutritional Assessment, the Timed Up and Go test, and activities of daily living, in 100 patients >70 years old. The Mini Nutritional Assessment and Timed Up and Go tests remained significant after adjustment. Green et al 17 assessed frailty using gait speed, grip strength, activities of daily living, and albumin in 159 TAVR patients and found that frailty was associated with higher 1-year mortality (hazard ratio, 3.51; 95% CI, 1.43-8.62). Finally, 2 other small studies of 100 to 200 patients also found higher mortality in frail patients after adjustment. 21, 22 Our study demonstrates the average gait speed observed in a large TAVR cohort and confirms the utility of gait speed as a single marker of frailty. The slowest walkers were older, more often female, and obese, with a higher prevalence of previous stroke, chronic lung disease, and heart failure. These comorbid conditions likely contribute to shortness of breath, which leads to both symptom-based referral and adverse outcomes after TAVR. 23, 24 Conversely, no association was observed between the slowest walkers and reduced left ventricular ejection fraction or elevated serum creatinine, which are 2 known risk factors for mortality in cardiovascular populations. [25] [26] [27] [28] Gait speed is a predictor of nonfatal outcomes and resource use in TAVR patients. Additionally, gait speed has been shown to predict length of stay and discharge location among those admitted to an acute care hospital, 29 but this has not been previously demonstrated in a TAVR population. Despite there not being a significant difference in complications such as stroke, acute kidney injury, and a life-threatening bleed, the slowest walkers had more vascular access-site complications and a longer duration of hospital stay. Moreover, the slowest walkers were likely to be discharged to extended care, hospice, or nursing homes. In addition to helping improve decision making with regard to TAVR, gait speed may help identify the patients who would most likely benefit from prehabilitation, which is a form of training aimed at preventing injury and strengthening reserves. 30, 31 Gait speed assessments should be incorporated into a multistep pathway, inclusive of comprehensive geriatric consultation and comorbidity review. 32 Gait speed, as a continuous variable and with cut points, is predictive of morbidity and mortality in older adults across a range of settings: community populations, 10 those with cardiovascular disease, 33 those with acute coronary syndrome, 34, 35 and patients undergoing percutaneous coronary intervention 11 or cardiac surgery. 13, 36, 37 The median gait speed in communitydwelling populations (mean age, 72-79 years) is reported to be 0.92 m/s. 10 In elderly patients with heart failure 12 and those undergoing cardiac surgery, 13 the median gait speed is reported to be 0.76 m/s. These medians are substantially higher than the median gait speed that we found in our population, which was 0.63 m/s. Our data are more in line with the median gait speed of 0.57 m/s found in a TAVR referral population 17 and 0.38 m/s found in a substudy of the Placement of Aortic Transcatheter Valve (PARTNER) trial. 38 Previously, a gait speed of 0.83 m/s has been proposed as a cutoff with good discrimination properties in a population with heart failure 12 and a population undergoing cardiac surgery. 13 However, >75% of our TAVR population had a gait speed of <0.83 m/s, and one quarter had a gait speed of <0.5 m/s. The slowest walkers had significantly higher mortality than walkers with normal or slow gait speed, whereas slow walkers (0.5-0.83 m/s) did not differ from normal walkers. These findings support a lower gait speed cutoff of <0.5 m/s as a discriminator of risk within an already frail TAVR population with severe valve disease and symptom-driven referral. 17
Limitations
Our study had several limitations. First, although the majority of eligible patients had gait speed data reported, slightly more than one third had no gait speed data reported. We have no information determinative of why the test was not performed in these individuals, but clinical differences between patients who had the test performed were not pronounced, suggesting that logistical factors were the hindrance. The 8% of patients who were reported as being unable to walk were considered high risk, at least from a walking test perspective. Patients who were unable to walk had more comorbidities and worse outcomes than the rest of the population; however, we did not include these patients because of the vast variety of reasons that they were unable to walk. Second, we used gait speed as a measure of frailty. Arguably, because frailty is a multifaceted condition, it needs assessment in several domains. 32 Nonetheless, gait speed has excellent reproducibility, is simple to execute, and predicts mortality and morbidity better than grip strength, 
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the Timed Up and Go test, and more complex measures. 11, 39 Therefore, an initial assessment with gait speed offers a method that is informative, inexpensive, and simple. Third, 1-year outcomes are not presented in this report. Future work is needed to explore the relationship of gait speed with 1-year mortality and cause of death. Nevertheless, adding gait speed to the STS-PROM 30-day measure is important, especially in relation to an invasive treatment such as TAVR. Finally, even though this is the largest study to assess frailty in a clinical context, the population may still have been too small to detect differences in secondary end points such as bleeding and stroke.
Conclusions
The 5-m gait speed test is an important tool for assessing frailty in a population referred for TAVR, providing reassurance with regard to normal walkers and targeting the slowest walkers for more evaluation. 
